References
- 1. Hu X, Bonde Y, Eggertsen G, Rudling M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism, J Intern Med, 2014;275:27-38.
- 2. Klaassen CD, Cui JY, Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids, Drug MetabDispos, 2015; Aug 10. pii:dmd.115.065698. [Epub ahead of print].
- 3. Li T, Chiang JY. Bile acids as metabolic regulators, CurrOpinGastroente rol, 2015;31:159-165.
- 4. Louis P, Hold GL, Flint HJ. The gut microbiota, bacterial metabolites and colorectal cancer, Nat Rev Microbiol, 2014;12(10):661-72.
- 5. Chapman CG, Rubin DT. The potential for medical therapy to reduce the risk of colorectal cancer and optimize surveillance in inflammatory bowel disease, GastrointestEndoscClin N Am, 2014;24(3):353-65.
- 6. Dongfeng D, An C, Shujia P et al. Explanation of colon cancer pathophysiology through analyzing the disrupted homeostasis of bile acids, Afr Health Sci, 2014;14(4):925-8.
- 7. Barrasa JI, Olmo N, Lizarbe MA, Turnay J. Bile acids in the colon, from healthy to cytotoxic molecules, Toxicol In Vitro, 2013;27(2):964-77.
- 8. Degirolamo C, Modica S, Palasciano G, Moschetta A. Bile acids and colon cancer: Solving the puzzle with nuclear receptors, Trends Mol Med, 2011;17(10):564-72.
- 9. Wang Y, Cui P. Reactive Carbonyl Species Derived from Omega-3 and Omega-6 Fatty Acids, J Agric Food Chem, 2015;63(28):6293-6.
- 10. Vangaveti VN, Jansen H, Kennedy RL, Malabu UH. Hydroxyoctadecadienoic acids: Oxidised derivatives of linoleic acid and their role in inflammation associated with metabolic syndrome and cancer, Eur J Pharmacol, 2015; May 15. pii:S0014-2999(15)00460-4.
- 11. Lim SC, Han SI. Ursodeoxycholic acid effectively kills drug-resistant gastric cancer cells through induction of autophagic death, Oncol Rep, 2015;34(3):1261-8.
- 12. Serfaty L. Chemoprevention of colorectal cancer with ursodeoxycholic acid: pro, Clin Res HepatolGastroenterol, 2012;36 Suppl1:S53-60.
- 13. Carey EJ, Lindor KD. Chemoprevention of colorectal cancer with ursodeoxycholic acid: cons, Clin Res HepatolGastroenterol, 2012;36 Suppl1:S61-4.